» Articles » PMID: 30105666

Risk Factors and Prediction Model for Persistent Breast-cancer-related Lymphedema: a 5-year Cohort Study

Overview
Specialties Critical Care
Oncology
Date 2018 Aug 15
PMID 30105666
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Breast-cancer-related lymphedema (BCRL) can be a transient or persistent condition. The aims of this study were to (1) identify and weigh the risk factors for persistent lymphedema (PLE) among all patients with BCRL and (2) establish a prediction model for the occurrence of PLE.

Methods: A cohort of 342 patients with BCRL with a median follow-up of 5 years after the onset of swelling was analyzed. PLE was defined as a hardening of the subcutaneous tissue, the persistence of the circumferential difference (CD) between arms, or a flare-up of swelling during follow-up. Multiple logistic regression was used to identify risk factors for PLE, including tumors, treatments, and patient-related factors. The prediction accuracy of the model was assessed using the area under the receiver operating characteristic curve (AUC).

Results: Of the 342 patients with BCRL, 229 (67%) had PLE. Multiple logistic regression analysis revealed that the number of lymph node metastases (p = 0.012), the maximal CD between arms at the first occurrence of swelling (p < 0.001), and the largest difference during follow-up (p < 0.001) were significant predictors for PLE. The corresponding AUC was 0.908. Although inclusion of body weight gains (p = 0.008) and maximal CD at the latest follow-up (p = 0.002) increased the analytical accuracy (AUC = 0.920), the resulting AUC values (p = 0.113) were not significantly different.

Conclusions: BCRL is persistent in two thirds of patients. Patients with more lymph node metastases, weight gain, and larger CD since the onset of swelling and during follow-up have an increased likelihood of developing PLE.

Citing Articles

Protective Factors Associated with Normal Lymphatic Function After Axillary Lymph Node Dissection for Breast Cancer Treatment.

Coleman-Belin J, Rubin J, Boe L, Diwan R, Monge J, Dinh D Ann Surg Oncol. 2025; .

PMID: 39899216 DOI: 10.1245/s10434-025-16918-5.


External Validation of a 5-Factor Risk Model for Breast Cancer-Related Lymphedema.

Lin C, Su J, Wu A, Lin N, Hossack M, Shi W JAMA Netw Open. 2025; 8(1):e2455383.

PMID: 39836421 PMC: 11751742. DOI: 10.1001/jamanetworkopen.2024.55383.


Factors affecting lymphedema after neoadjuvant chemotherapy and axillary dissection in female breast cancer patients: a retrospective cohort study based on the Chinese population.

Fu J, Chen R, He L, Bao L, Lin Z, Jiang W Front Oncol. 2024; 14:1436748.

PMID: 39600650 PMC: 11590064. DOI: 10.3389/fonc.2024.1436748.


Development and validation of a nomogram for breast cancer-related lymphedema.

Jiang Q, Hu H, Liao J, Li Z, Tan J Sci Rep. 2024; 14(1):15602.

PMID: 38971880 PMC: 11227568. DOI: 10.1038/s41598-024-66573-1.


Development of predictive models for lymphedema by using blood tests and therapy data.

Trinh X, Chien P, Long N, Van Anh L, Giang N, Nam S Sci Rep. 2023; 13(1):19720.

PMID: 37957217 PMC: 10643602. DOI: 10.1038/s41598-023-46567-1.


References
1.
Velanovich V, Szymanski W . Quality of life of breast cancer patients with lymphedema. Am J Surg. 1999; 177(3):184-7; discussion 188. DOI: 10.1016/s0002-9610(99)00008-2. View

2.
Petrek J, Senie R, Peters M, Rosen P . Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer. 2001; 92(6):1368-77. DOI: 10.1002/1097-0142(20010915)92:6<1368::aid-cncr1459>3.0.co;2-9. View

3.
Bronstad A, Berg A, Reed R . Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol. 2004; 287(2):H963-8. DOI: 10.1152/ajpheart.01052.2003. View

4.
Soran A, DAngelo G, Begovic M, Ardic F, Harlak A, Wieand H . Breast cancer-related lymphedema--what are the significant predictors and how they affect the severity of lymphedema?. Breast J. 2007; 12(6):536-43. DOI: 10.1111/j.1524-4741.2006.00342.x. View

5.
McLaughlin S, Wright M, Morris K, Giron G, Sampson M, Brockway J . Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008; 26(32):5213-9. PMC: 2652091. DOI: 10.1200/JCO.2008.16.3725. View